SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001337553-21-000009
Filing Date
2021-11-04
Accepted
2021-11-04 16:05:07
Documents
13
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeri-20211104.htm   iXBRL 8-K 43749
2 EX-99.1 aeri-3q21ex991earningsrele.htm EX-99.1 160496
  Complete submission text file 0001337553-21-000009.txt   359017

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aeri-20211104.xsd EX-101.SCH 1924
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aeri-20211104_lab.xml EX-101.LAB 24132
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aeri-20211104_pre.xml EX-101.PRE 12526
6 EXTRACTED XBRL INSTANCE DOCUMENT aeri-20211104_htm.xml XML 11689
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 211379871
SIC: 2836 Biological Products, (No Diagnostic Substances)